Hattie Hayes

Biocon’s YESAFILI is intended for treatment of a number of ocular conditions, including neovascular AMD, visual impairment due to myopic choroidal neovascularisation, visual impairment due to DME and visual impairment due to macular edema secondary to retinal vein occlusion.

The endorsement follows FDA approval in the United States this summer.

Mary Elizabeth Hartnett, MD, FACS, discussed the impact of blindness and vision loss on women in the United States.

The new range of pure and premixed gases are intended for medium-term use in retinal surgery.

Ali Erginay, MD, of Lariboisière Hospital in Paris, France, discusses his EURETINA presentation, "Introducing optomap® Ultra-widefield Colour Red-Green-Blue Multimodal Imaging."

Our team spoke to Varun Chaudhary, MD, about his EURETINA presentation, titled "Systematic Review and Metanalysis in Macular Hole RCTs – Posturing after Macular Hole Surgery."

Novartis acquired Gyroscope Holdings Limited from Syncona in February 2022.

The non-profit will partner with the imaging company to prevent blindness and fund new retinoblastoma research.

European Medicines Agency issued approval for a Clinical Trial Application of its new gene therapy, VG901, which uses an adeno-associated virus vector to treat CNGA1-associated retinitis pigmentosa.

The study met its primary efficacy endpoint for the neovascular age-related macular degeneration (nAMD) treatment.

Tenpoint’s aim is to reverse vision loss by generating specialized ocular cell types, both ex vivo and in vivo.

Margaret Chang, MD, MS, spoke with Modern Retina to give an update on avacincaptad pegol for geographic atrophy.